211 related articles for article (PubMed ID: 30343006)
1. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M
J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346
[TBL] [Abstract][Full Text] [Related]
4. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
[TBL] [Abstract][Full Text] [Related]
5. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
[TBL] [Abstract][Full Text] [Related]
6. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
[TBL] [Abstract][Full Text] [Related]
7. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer.
Haratake N; Toyokawa G; Takada K; Kozuma Y; Matsubara T; Takamori S; Akamine T; Katsura M; Shoji F; Okamoto T; Oda Y; Maehara Y
Ann Thorac Surg; 2018 Feb; 105(2):448-454. PubMed ID: 29254651
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
12. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H
Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880
[TBL] [Abstract][Full Text] [Related]
14. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
15. Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression.
Toyokawa G; Takada K; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Nov; 18(6):e375-e383. PubMed ID: 28385373
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
17. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
18. High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas.
Toyokawa G; Takada K; Okamoto T; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):504-511.e1. PubMed ID: 28038981
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung.
Hirai A; Yoneda K; Shimajiri S; Kuroda K; Hanagiri T; Fujino Y; Tanaka F
J Thorac Cardiovasc Surg; 2018 Jan; 155(1):382-392.e1. PubMed ID: 28711324
[TBL] [Abstract][Full Text] [Related]
20. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.
Wu S; Wu D; Pan Y; Liu H; Shao Z; Wang M
Pathol Res Pract; 2019 Feb; 215(2):292-301. PubMed ID: 30527357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
